This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
CD30 is the target of the FDA approved therapeutic Brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. It is approved for use in:
1) Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
2) HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
3) Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen 
^Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi (in Chinese) 34 (11): 711–5. PMID16536313.
^Gorczyca W, Tsang P, Liu Z et al. (February 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". Int. J. Oncol.22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID12527929.CS1 maint: Explicit use of et al. (link)
^ abAizawa, S; Nakano H; Ishida T; Horie R; Nagai M; Ito K; Yagita H; Okumura K; Inoue J; Watanabe T (January 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". J. Biol. Chem.272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID8999898.
Schneider C, Hübinger G (2003). "Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family". Leuk. Lymphoma43 (7): 1355–66. doi:10.1080/10428190290033288. PMID12389614.
Dürkop H, Latza U, Hummel M et al. (1992). "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease". Cell68 (3): 421–7. doi:10.1016/0092-8674(92)90180-K. PMID1310894.CS1 maint: Explicit use of et al. (link)
Josimovic-Alasevic O, Dürkop H, Schwarting R et al. (1989). "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay". Eur. J. Immunol.19 (1): 157–62. doi:10.1002/eji.1830190125. PMID2537734.CS1 maint: Explicit use of et al. (link)
Stein H, Gerdes J, Schwab U et al. (1983). "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". Int. J. Cancer30 (4): 445–59. doi:10.1002/ijc.2910300411. PMID6754630.CS1 maint: Explicit use of et al. (link)
Jung W, Krueger S, Renner C et al. (1995). "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Mol. Immunol.31 (17): 1329–34. doi:10.1016/0161-5890(94)90051-5. PMID7527901.CS1 maint: Explicit use of et al. (link)
Shiota M, Fujimoto J, Semba T et al. (1994). "Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3". Oncogene9 (6): 1567–74. PMID8183550.CS1 maint: Explicit use of et al. (link)
Gedrich RW, Gilfillan MC, Duckett CS et al. (1996). "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins". J. Biol. Chem.271 (22): 12852–8. doi:10.1074/jbc.271.22.12852. PMID8662842.CS1 maint: Explicit use of et al. (link)
Horie R, Ito K, Tatewaki M et al. (1996). "A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages". Blood88 (7): 2422–32. PMID8839832.CS1 maint: Explicit use of et al. (link)
Aizawa S, Nakano H, Ishida T et al. (1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". J. Biol. Chem.272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID8999898.CS1 maint: Explicit use of et al. (link)
Boucher LM, Marengère LE, Lu Y et al. (1997). "Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily". Biochem. Biophys. Res. Commun.233 (3): 592–600. doi:10.1006/bbrc.1997.6509. PMID9168896.CS1 maint: Explicit use of et al. (link)
Mizushima S, Fujita M, Ishida T et al. (1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)". Gene207 (2): 135–40. doi:10.1016/S0378-1119(97)00616-1. PMID9511754.CS1 maint: Explicit use of et al. (link)
Kurts C, Carbone FR, Krummel MF et al. (1999). "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells". Nature398 (6725): 341–4. doi:10.1038/18692. PMID10192335.CS1 maint: Explicit use of et al. (link)